Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. - Wikidata - awgldk - TriplyDB

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

http://www.wikidata.org/entity/Q33429255

about

Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.Targeting protein quality control pathways in breast cancer.Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.Targeting triple negative breast cancer with histone deacetylase inhibitors.Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.

P2860

Q33443179-07AFC5C7-F597-4C07-9E8E-540498A85377 Q46087491-EC00B1F8-2C1F-453D-B0E2-05E220ED5611 Q47130486-85C8EBE1-EB94-4F4F-9549-CA70C708A817 Q47927498-DEDD224A-A13E-41B6-A62E-73B92E98E12C Q49544302-F1C261C6-6399-4B60-B463-1B45EC4CE32C

P2860

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

http://www.wikidata.org/entity/Q33429255

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@ast

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@en

type

label

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@ast

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@en

prefLabel

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@ast

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@en

P1433

Q33429255-1816FB23-F637-48C2-A30C-8E8E972116BA

P1476

Q33429255-B7DC8A65-38FA-4E9A-9989-56ADDDE476CC

P2093

Q33429255-2A3433FC-9135-47EB-9AED-B0ED41F73DF9

Q33429255-8461346B-E36F-431E-BC65-6295ADD0E3C5

Q33429255-93464B1D-D04A-4BBE-A31D-B38C57CA160B

Q33429255-A15468D2-5721-4052-98E4-67D24851477E

Q33429255-AB45EAD0-E199-4DDD-84B4-4E7F6D9A9103

Q33429255-B481A8B6-F85A-497B-A277-85E8F3D881F7

Q33429255-F0CE3A02-32EC-4FE4-AF21-1ABD8AF0A2F8

P2860

Q33429255-3CB8F58A-BD0B-44BB-A18B-B826D7C883F4

Q33429255-41D14B56-8F10-4819-B1DA-23FDD47FD80A

Q33429255-7C1F7B8F-9702-422F-8725-E3A83C405A14

Q33429255-7FDB892A-0B56-4034-9F5B-DE9100576716

Q33429255-9A952975-8DB3-4DAB-952F-A6114A509450

Q33429255-C51232BC-9C2D-4733-908B-C8FBBC104F07

Q33429255-C60326EC-454E-4D41-A098-165A8BE3208E

Q33429255-E115394F-D844-4D6B-A376-D76F4704181C

Q33429255-E712E2D8-A730-4B84-93E8-AB41A59197FE

Q33429255-FAB168B9-D293-4026-8F14-13AFF4533192

P304

Q33429255-88F74F69-240E-4E12-8785-B30EDA1AD895

P31

Q33429255-B11DF0C1-332D-4455-81D3-0A9E7CD1205C

P356

Q33429255-8FDA3A12-B622-40B9-A1B5-EE7F0EEC36C5

P407

Q33429255-337FDAAD-E05D-4D97-992D-2BDC4F749F56

P433

Q33429255-8B46E5D0-1000-4C74-ACD4-F1E29D1CE096

P478

Q33429255-E7B03585-0E8C-4932-8D0B-3B3CB605A71D

P577

Q33429255-779ECC91-AA0E-425F-B9A7-05BE5658FCB9

P698

Q33429255-7EF9E43A-8EB1-4B0A-9F4A-D6A8EA3C127F

P932

Q33429255-3F0BB7D6-D767-4EDD-9AA5-B58CFF7F9A05

P356

J.CLBC.2015.11.003

P1433

Clinical Breast Cancer

P1476

Phase I Study of Panobinostat ...... static Breast Cancer Patients.

@en

P2093

Alvaro Moreno-Aspitia

http://www.w3.org/2001/XMLSchema#string

Donald W Northfelt

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Jacob B Allred

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Matthew P Goetz

http://www.w3.org/2001/XMLSchema#string

Winston W Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Anticancer activities of histone deacetylase inhibitors

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

HDAC inhibitors: clinical update and mechanism-based potential.

P304

82-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLBC.2015.11.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26774555

http://www.w3.org/2001/XMLSchema#string

P932

5567753

http://www.w3.org/2001/XMLSchema#string